National Cancer Institute: Opportunities for Cooperative Research and Development Agreements (CRADAs) for the Joint Evaluation and Development of Methods to Generate and Expand In-Vitro Modified Dendritic Cell Populations in Order to Elicit Phenotype Specific Immune Responses

Riepilogo

Pursuant to the Federal Technology Transfer Act of 1986 (FTTA, 15 U.S.C. 3710; and Executive Order 12591 of April 10, 1987, as amended by the National Technology Transfer and Advancement Act of 1995), the National Cancer Institute (NCI) of the National Institutes of Health (NIH) of the Public Health Service (PHS) of the Department of Health and Human Services (DHHS) seeks Cooperative Research and Development Agreements (CRADAs) with pharmaceutical or biotechnology companies to evaluate and develop methods to generate, expand and modify dendritic cells to act in an immunologically specific manner. The Collaboration will focus on the development and evaluation of conditions for specific immunomodulatory maneuvers focused on induction of Th1 and Tc1 biased immune responses by dendritic cells. Additionally, the collaboration will include the characterization of human dendritic cell phenotypic subsets including the generation of subset specific reagents. These research efforts would be directed by our evolving understanding of dendritic cell biology which includes both the characterization of cytokine expression by dendritic cells (production and regulation of production) and the charac